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Summary
The nsk of hemorrhage when usmg coumann anticoagulants sharp-
ly mcreases when the International Normahsed Ratio (INR) is >60
We performed a prospective cohort study with a nested case-control de-
sign among 17,056 outpatients of an anücoagulation clinic to determme
the mcidence of Overanticoagulation and to study the association
between Overanticoagulation and charactenstics of anticoagulant thera-
py and comorbidity The mcidence rate of an INR >6 0 was 7 8 pei
10,000 treatment days m prevalent users on the startmg date and 22 5
per 10,000 treatment days m incident users dunng the study penod
300 cases with an INR >6 0 were compaied with 302 randomly select-
ed matched controls with an INR withm the target zone Patients on
acenocoumarol had an mcreased nsk of an INR >6 0 compared to pa-
tients on phenprocoumon Regardmg comorbidity, impaired liver func
tion, congestive heart failure, diarrhea and fever were nsk factors for
oveianticoagulation Increased momtonng of INR values if nsk factors
are present or avoidance of nsk factors could prevent excess anticoagu
lation and potential bleedmg comphcations
Introduction
Coumarm anticoagulants are clmically effective m the prevention of
venous and artenal thiomboembohsm (1) These drugs induce antico-
agulation by antagomsmg vitamm K, thereby impainng the biological
activity of the vitamm K dependent coagulation factors (factor II, VII,
IX and X) (2) Inherent to their mode of action and narrow therapeutic
mdex, hemorrhage is the most common adverse reaction to coumann
anticoagulants The nsk of hemorrhage is strongly associated with the
mtensity of anücoagulation and sharply mcreases when the INR is >6 0
(3-6) Such an excess anticoagulant effect should therefore be prevent-
ed This necessitates Identification of nsk factors for Overanticoagula-
tion
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A number of comorbidities are suspected to enhance the response to
coumarms (7 10) Hepaüc dysfunction may impair the synthesis of co-
agulation factors In hypermetabolic states the clearance of coagulation
factors is mcreased Fat malabsorption and diarrhea impair the absorp-
üon of vitamm K With mahgnancies, the metabohsm of vitamm K and
the coumarm anticoagulant may be affected In congestive heart failure
the distnbution of the coumann anticoagulant is altered
The stability of anticoagulant control depends on the type of antico
agulant used and has been found to be less when usmg the short-acting
acenocoumarol because of fluctuating factor VII levels (11, 12) In ad-
dition, the patient's comphance plays a role m stability of control (13,
14) Possibly the nsk of oveianticoagulation is also related to these fac-
tors
The occurrence of Overanticoagulation m a non selected population
undei everyday circumstances and the association between Overantico-
agulation and charactenstics of anticoagulant therapy and comorbidity,
have not been studied extensively Therefore, we have conducted a
prospective cohort study with a nested case control design among out-
patients of an anücoagulation clinic We determmed the mcidence of
Overanticoagulation (INR >60) and studied the association between
Overanticoagulation and charactenstics of anticoagulant therapy and
comorbidity m previously stable patients This paper is one of a senes
of three papers on nsk factors for Overanticoagulation The othei two
papers are based on the same study and concern drug mteracüons and
sociodemographic, hfestyle, and dietary factors
Methods
Settmg
In the Netherlands, anticoagulant therapy is momtored by a network of more
than 60 mdependently operatmg speciahsed anticoagulation clmics, covermg
over 90% of the country (l *>, 16) The study was performed at the regional Re(j
Cross anticoagulation clinic The Hague, which serves an area of nearly 700,000
mhabitants All persons in this area with an mdication for anticoagulant thera-
py are referred to this clinic
Cohort Definition
The study cohort consisted of all patients treated with oral anticoagulants by
the regional Red Cross anticoagulation clinic The Hague between l December
1997 and 14 June 1999 The cohort therefore mcluded prevalent users on the
startmg date and incident users dunng the study penod All cohort members
were followed until the first occurrence of an INR >6 0, the end of their treat
ment, or the end of the study penod (i e the day on which the planned number
of cases was recruited), whichever came first
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Cases and Controh
Subjects for the nested case-control study were idenüfied daily from all pa-
tients with an INR measurement on that day Cases were defmed äs cohort
members with an INR >6 0 For each case, one control, matched on therapeutic
ränge, was randomly selected from the cohort members with an INR withm the
target zone (2 0 3 5 or 2 5-4 0), measured on the same day äs the case (mdex
day) Overanticoagulation is often seen dunng Initiation of anticoagulant thera-
py and m unstable anticoagulation Smce this was not our pnmary mterest, on-
ly cases and controls with stable anticoagulation m the three months preceding
the mdex day were ehgible Anticoagulant therapy is considered effective and
safe if the patient is kept withm the target zone for more than two-third of the
time (17, 18) Therefore, we defmed stable anticoagulation äs havmg at least
66% of the INRs withm the target zone and no INRs >5 5 m the three months
preceding the mdex day To judge stabihty, a mmimum of three INRs had to be
assessed m the three months preceding the mdex day Cases and controls with
a hospital admission m this penod were excluded, since Information on antico-
agulant control dunng admission is often not available at the anticoagulation
clmic As we focussed on sudden Overanticoagulation, the INR preceding the
assessment on the mdex day had to be withm the target zone Patients who were
not hvmg mdependently and those makmg use of meals on wheels were exclud-
ed because these patients may be less able to rehably answer the questions on
medication and diet Smce we were pnmanly mterested m Overanticoagulation,
irrespective of the question whether this was followed by hemorrhage, patients
who presented at the mdex day with a senous bleedmg comphcation were ex-
cluded because this may promote recall bias
Procedure
The study protocol has been approved by the Medical Ethics Committee of
the Erasmus Umversity Medical Center Rotterdam We planned to recruit
300 cases and 300 controls to provide at least 80% power to detect a true odds
ratio (OR) of >2 0 for nsk factors havmg a prevalence of 7% among the con-
trols, usmg a p <0 05 to reject the null hypothesis of OR = l
Information on charactenstics of anticoagulant therapy and comorbidity, äs
well äs on potential confoundmg factors, was collected from the anticoagulant
medical record, through the general practitioner (GP) and the pharmacy, and by
mterviewmg the patient The interview took place withm three weeks after the
mdex day at the private address of the patient, makmg use of structured ques-
tionnaires with mamly closed questions The Interviewers were blmded with re-
spect to the patient's case or control Status and the specific research hypotheses
This also applied to the GPs and the pharmacists Blmdmg of the patients was
not fully feasible, smce the INR value is prmted on their dosage hst To obviate
this, m the Information letter we referred to the problem of Overanticoagulation
m a general sense
Charactenstics of Anticoagulant Therapy and Comorbidity
The nsk penod was defmed äs the four-week penod preceding the mdex
day The followmg charactenstics of anticoagulant therapy were collected from
the anticoagulant medical record mdication for anticoagulation, duration of
therapy (categonsed äs < l year, l to 5 years and >5 years, exclusive of former
treatment episodes), type of anticoagulant used, change of type of anticoagulant
m the nsk penod, and the latest dosage of the anticoagulant The patient was
asked about compliance with anticoagulant therapy, i e regulanty of pill mtake
and missed or extra pills m the nsk penod With respect to comorbidity, chron-
ic comorbidities äs well äs acute illnesses dunng the nsk penod were taken mto
account The GP was asked whether the patient had an impaired hver, bihary or
pancreatic function, an impaired gastro-mtestmal absorption, congestive heart
failure, hyperthyroidism, or a malignancy. If so, it was asked whether the con-
dition had changed m the nsk penod Smce anticoagulant therapy hkely is ti-
trated to chromc comorbidities and only a relapse or change may be related to
Overanticoagulation, all chromc comorbidities were categonsed äs absent,
stable m the nsk penod, and worsened m the nsk penod Regardmg acute ill-
nesses, the patient was asked about havmg been ill m the nsk penod and if so,
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Fig l The cumulative mcidence of the occurrence of an INR >6 0 m mcident
(A) and prevalent (B) users of acenocoumarol or phenprocoumon
about his or her complamts and the presence of fever (a temperature >38° C)
In addition, the GP was asked whether the patient had consulted him m the nsk
penod and if so, with which medical problems
Cofactors
Acute illnesses and worsened chromc comorbidities may be accompamed
by a change m drug use (beside the anticoagulant), weight, physical activity,
dietary mtake (and thereby mtake of vitamm K), and/or alcohol consumption
These factors may also affect the response to oral anticoagulants (19-24) and
were thus considered äs potential confounders The associations between these
cofactors and Overanticoagulation are the mam subjects of the two other papers
mentioned m the mtroduction
Statistical Analyse!,
We calculated the cumulative mcidence of an INR value >6 0 usmg the
Kaplan-Meier method, äs well äs the mcidence rate Both mcidence measures
were calculated separately for prevalent users on the startmg date and mcident
users durmg the study penod, smce Overanticoagulation is often seen durmg m-
itiation of anticoagulant therapy
Charactenstics of anticoagulant therapy and comorbidity related to an INR
>6 0 were identified usmg umvanate conditional logistic regression analysis at
first Smce the unconditional analyses gave comparable results but more statis-
tical power, we fmally used unconditional logistic regression to compute unad-
justed odds ratlos and their 95% confidence mtervals In case a nsk factor was
absent m either the cases or the controls, a Fisher Exact lest was performed m-
stead
To assess charactenstics of anticoagulant therapy and stable chromc comor-
bidities that were mdependently associated with an INR >6 0, all factors of
these two categones which were umvanately associated at a p <0 10, age, sex,
and the number of INR determmations m the preceding three months were m-
cluded m a multiple regression model A comparable procedure was followed
to assess worsened chromc comorbidities and acute illnesses that were mdepen-
dently associated with an INR >6 0 Cofactors which were umvanately asso-
ciated with an INR >6 0 were mcluded äs well if this resulted m a change m one
of the odds ratios of 5% or over, startmg with the most potent factor
In order to determme the importance of the mdependent nsk factors for
Overanticoagulation m the population, we calculated the population attnbutable
nsk percentages (PAR%) accordmg to the followmg formula (25)
PAR% = AR% * (proportion of exposed cases), with AR% = ((OR-1 )/OR) * 100
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l to 5 years
i l year
122 138 l [reference]
125 115 1.2 [0.9-1 8]




165(55%) 200(66%) l [reference]
135(45%) 102(34%) 1.6 [l 1-2 2]
l [reference]'
l 9 [l 3-2 7]f
Change of type of anticoagulant l 0 [0.1-16 2]
Dosage of anticoagulant (mg/day, meanisd)
phenprocoumon 0 83 ± 0 53 0 76 ± 0.30 l 5 [0.9-2 6]
acenocoumarol 2 93 ± l 35 2 73 ± l .20 l. l [0 9-1 4]
Comphance
no regulär mtake of anticoagulant
pills rmssed




9 l 5 [0.6-3.5]
23 1.1 [0.6-1.9]
0 p=0.02
Values are numbers unless indicatcd otherwise
* Type of anticoagulant, stable congestive heart failure, stable impaired liver function, age, gender and the number
of INR determmations m the precedmg three months were included m the model.
Results
The prospective cohort consisted of 17,056 patients: 9,508 prevalent
users on the starting date, who had on average 380 treatraent days
(ränge l to 560 days) and 16 INR measurements (ränge 0 to 72 meas-
urements) and 7,548 incident users during Ihe study period, who had on
average 98 treatment days (ränge l to 558 days) and 9 INR measure-
ments (ränge l to 60 measurements). The cumulative incidence of the
occurrence of an INR value >6.0 is represented in Fig 1. As expected,
Overanticoagulation occurred more often in incident users. After six
months of follow up, the cumulative incidence was 17% in prevalent
users and 29% in incident users. After one year it was 25% and 39% re-
spectively, and at the end of the study period, i.e. after 560 days of fol-















illness of the unnary tract






























OR [95% Cl] OR [95% CI] ^ ̂ ^f10" ^ween ov(™,lt„ Ul
laüon (INR >6 0) and comorbidrty*
umvanate multivanate
15 [098 2 3] 16 [104 2 6]'
1 1 [062 1]
2 7 [11 6 5] 2 8 [1169]'
1 3 [0 5 3 5]
1 3 [0 3 6 0]
0 3 [0 0 3 2]
5 3 [15 188] 30 [08 120]'
2 0 [0 4 112]
60[1 7 207] 12 8 [1 6 1049]'
40 [15 109] 12 [04 4 2]'
2 1 [1 4 3 1] 1 0 [0 5 1 7]'
53 [26 107] 2 9 [1 1 77]'
Values are numbers
Stable congestive heart failure stable impaired hver function type of anticoagulant age gender and the number
of INR determmations in the precedmg three months were included m the model
Relapseof congestive heart failure diarrhea illness of the unnary tract illness of the respiratory tract fever age
gender the number of INR determmations m the precedmg three months use of antibactenal drugs use of
analgesics & NSAIDs change m weight change in physical activity and change m frequency of suppers were
included m the model
m mcident users The number of prevalent users with an INR >6 0 was
2,813, which is correspondmg to an mcidence of 18 per 1000 INR
measurements and an mcidence rate of 7 8 per 10,000 treatment days
l 663 mcident users had an INR >6 0, the mcidence bemg 26 per 1000
INR measurements and the mcidence rate bemg 22 5 per 10,000 treat
ment days
The nested case control study included the planned number of 300
cases with a median INR of 6 8 and 302 controls with a median INR of
3 2 The participation among cases and controls was 78% and 85% re-
spectively Wntten mformed consent was obtamed from every patient
The mean mterval between the mdex day and the interview was four-
teen days, for cases äs well äs for controls In both case and control
groups, the mean age was 68 years, the proportion of men was 58% and
64% respectively
The associations between overanticoagulation and charactenstics of
anticoagulant therapy are shown m Table l The mdication for antico
agulation and the duration of therapy were not related to an INR >6 0
Neither was the dosage of the anticoagulant The type of anticoagulant
used, however, was a nsk factor for overanticoagulation Patients on
acenocoumarol had an mcreased nsk of l 9 (95%CI l 3-2 7) compared
to patients on phenprocoumon The PAR% of overanticoagulation äs
sociated with the use of acenocoumarol was 213% A change of type of
anticoagulant occurred m only two patients Regardmg comphance six
cases but no controls had taken more pills than prescribed (p = 0 02)
With respect to comorbidity (Table 2), the only stable chiomt, co
morbidities related to overanticoagulation were impaired hvei function
and congestive heart failure The latter condition resulted m an m
creased nsk of an INR >6 0 of l 6 (95%CI l 04-2 6) The coirespond
mg PAR% was 7 5% Patients with an impaired hver function had an
mcreased nsk of 2 8 (95%CI l 1-69) None of these patients had livei
cirrhosis, one case and two controls had chromc active hepatitis In six
teen cases and m six controls, the hver function was otherwise impaned
(mcluding abnormal hver enzymes) and of two cases the kmd ot im
pairment was not stated by the GP The PAR% of overanticoagulation
associated with an impaired hver function was 3 9% A worsenmg ton
dition was mfrequent for most chromc comorbidities A relapse of con
gestive heart failure was present m fourteen cases and m three controls
and was umvanately associated with an mcreased nsk of overanticoag
ulation of 5 3 (95%CI l 5-18 8) After adjustment for confoundmg fac
tors the mcreased nsk was 3 0 (95%CI 08 120) The correspondmg
PAR% was 3 1% Regardmg acute illnesses, diairhea and fever wcic
nsk factors for overanticoagulation, with relative nsks of 12 8 (95%CI
l 6 104 9) and 2 9 (95%CI 11-77) respectively Stratifymg for duia
tion of fever (<4 days and >4 days) revealed an mcreased nsk öl an
572
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INR >60 m both strata (univanate OR 44 (95%CI l 6-12 1) and
OR 6 7 (95%CI 23-197) respectively) The PAR% of overanticoagu-
lation associated with diarrhea and fever were 5 2% and 9 8% respec-
tively Illnesses of the urmary or respiratory tract were only univanate-
ly associated with an mcreased nsk of an INR >6 0 (OR 4 0, 95%CI
l 5-10 9 and OR 2 l, 95%CI l 4-3 l respectively)
Discussion
We determmed the mcidence of Overanticoagulation among outpa-
tients of an anticoagulation climc Furthermore, we studied the associ-
ation between Overanticoagulation and charactenstics of anticoagulant
therapy and comorbidity The mcidence rate of an INR >6 0 was 7 8 per
10,000 treatment days in prevalent users on the startmg date and 22 5
per 10,000 treatment days m incident users durmg the study penod
Smce the patients' INRs were not measured daily, the real mcidence of
Overanticoagulation may be higher Patients with an impaired hver
function or congestive heart failure, äs well äs those usmg acenocouma
rol had an mcreased nsk of an INR >6 0 Fever and diarrhea were also
nsk factors for Overanticoagulation The clmical imphcation of our
fmdmgs lies m the possibihty of prevention or early detection of excess
anticoagulation, and thus of bleedmg comphcations, by paymg special
attention to these nsk factors when monitormg anticoagulation For ex-
ample, patients with an impaired hver function should be momtored
carefully and m case of fever, the patient's INR should be measured
withm seven days Similarly, the use of phenprocoumon mstead of
acenocoumarol might be considered This has been suggested before by
others (11,12), because of the more stable anticoagulant control when
usmg phenprocoumon compared to acenocoumarol
Diagnostic suspicion bias may play a role in the association of fever
and diarrhea with Overanticoagulation, smce patients are mstructed to
mform the climc of acute illnesses If considered necessary, the
patient's INR is measured earher than the appomted date Excludmg
patients whose INRs were measured earher from the analyses, fever
and diarrhea remamed nsk factors for Overanticoagulation
The presence of chromc comorbidities was based on GP diagnoses
Validation of drug use by reference to pharmacy data, revealed that
90% of the patients with a GP diagnosis of congestive heart failure had
mdeed used drugs for congestive heart failure or ischaemic heart dis-
ease
Although postulated äs mteractmg with anticoagulant therapy,
mahgnancy, an impaired gastro-mtestmal absorption, hyperthyroidism,
and an impaired bihary function were not related to Overanticoagulation
m our study Neither m case of a stable condition, nor m case of a re-
lapse in the nsk penod This may be explamed by the low prevalence of
some of these conditions, which requires a larger study population to at-
tam enough statistical power In addition, the mcrease in INR by the po
tentially mteractmg comorbidity may be of less magmtude than defmed
in our study
Comphance may mfluence the stability of anticoagulant control (13,
14) In our study, äs expected, takmg more pills than prescnbed was as-
sociated with Overanticoagulation We were not able to lest this associ-
ation multivanately, but m view of the clear-cut pharmacological path-
way this also would have been meanmgless Missmg pills and irregu-
larly takmg the anticoagulant were not related to Overanticoagulation
However, missmg pills occurred only occasionally (once or twice m the
four-week nsk penod) and patients who are constantly noncomphant
most probably will not become stable and therefore have been exclud-
ed a priori
So far äs we are aware of, epidemiological studies on nsk factor- cr
overanticoagulation m a non-selected population under ever\da\ —
cumstances are scarce and were only pubhshed for the first time -
1998 Two out of three earher studies (26, 27) have some hmitatioc?
Firstly, in one study (26), the cases were identified dunng a 12-mom:
penod whereas the controls were selected m June only In the --ecoa:
study (27), cases and controls do not seem to be time-matched eithe-
Secondly, the number of overanticoagulated patients was small (65 are
31 respectively) Thirdly, only univanate analyses were performed Tbe
third study (28) was well-performed Diarrhea and taking more warrjr-
m than prescnbed were determmants of an INR value >6 0, similar >.
our study On the contrary, advanced mahgnancy was a nsk tactor 7i.r
Overanticoagulation m their study, but fever was onl\ umvanateh a_sx-
ciated Impaired hver function, congestive heart failure, and iHnes^e- L
the urmary or respiratory tract were not considered by Hylek et al \r
important difference between the study of Hylek et al and our vtud\ -
that we only mcluded stable cases and controls Besides, we u^ee -
four-week nsk penod and they used a one week nsk penod La^th _t
study population of Hylek et al used warfann, while our patients us?_
phenprocoumon or acenocoumarol
Information on the mcidence of Overanticoagulation under e\ en cL·
circumstances is even scarcer than Information on nsk factors for o\er
anticoagulation In the study of Brigden et al (27) 0 3% of the INR?
were >6 0 In the study of Panneerselvam et al (26) 0 2% of the INR.-
were >7 0 When expressed m a comparable way, 2 0% of the INR·. -
our study were >6 0 and 0 9% of the INRs were >7 0 The much low r
mcidence of Overanticoagulation reported by Bngden et al and PAT-
neerselvam et al may be explamed by the lower target ränge ot antK\-
agulation m their studies
In conclusion, in this study among previously stable outpatient^
an anticoagulation climc, Overanticoagulation was associated w ith n.
type of anticoagulant used and with some comorbidities Increisi_
monitormg of INR values if nsk factors are present or avoidance öl r-»
factors, could prevent excess anticoagulation and potential bleed^.
comphcations
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